- Home
- PCRX vs EMO Comparison
PCRX vs EMO Comparison
Compare PCRX & EMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- EMO
- Stock Information
- Founded
- PCRX 2006
- EMO 2011
- Country
- PCRX United States
- EMO United States
- Employees
- PCRX N/A
- EMO N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- EMO Investment Managers
- Sector
- PCRX Health Care
- EMO Finance
- Exchange
- PCRX Nasdaq
- EMO Nasdaq
- Market Cap
- PCRX 1.2B
- EMO 837.1M
- IPO Year
- PCRX 2011
- EMO N/A
- Fundamental
- Price
- PCRX $23.22
- EMO $47.68
- Analyst Decision
- PCRX Buy
- EMO
- Analyst Count
- PCRX 8
- EMO 0
- Target Price
- PCRX $28.38
- EMO N/A
- AVG Volume (30 Days)
- PCRX 569.8K
- EMO 27.1K
- Earning Date
- PCRX 07-29-2025
- EMO 01-01-0001
- Dividend Yield
- PCRX N/A
- EMO 6.70%
- EPS Growth
- PCRX N/A
- EMO N/A
- EPS
- PCRX N/A
- EMO N/A
- Revenue
- PCRX $702,772,000.00
- EMO N/A
- Revenue This Year
- PCRX $7.54
- EMO N/A
- Revenue Next Year
- PCRX $10.78
- EMO N/A
- P/E Ratio
- PCRX N/A
- EMO N/A
- Revenue Growth
- PCRX 3.08
- EMO N/A
- 52 Week Low
- PCRX $11.16
- EMO $26.42
- 52 Week High
- PCRX $27.64
- EMO $40.17
- Technical
- Relative Strength Index (RSI)
- PCRX 35.42
- EMO 60.12
- Support Level
- PCRX $22.82
- EMO $47.11
- Resistance Level
- PCRX $24.36
- EMO $48.30
- Average True Range (ATR)
- PCRX 0.69
- EMO 0.82
- MACD
- PCRX -0.12
- EMO 0.14
- Stochastic Oscillator
- PCRX 17.09
- EMO 73.44
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.